论文部分内容阅读
目的研究Galectin-3在胃癌组织中的表达水平与临床病理之间的关系,初步探讨Galectin-3及Bcl-2在胃癌组织中表达的相关性。方法用免疫组化方法检测了60例胃癌患者的组织中Galectin-3及Bcl-2的表达,同时随机选择其中的15例癌旁组织作为对照组进行检测。结果胃癌组织中Galectin-3及Bcl-2的表达率分别为76.7%(46/60)和68.3%(41/60),远高于癌旁组织中的20%(3/15)和40%(6/15)。Galectin-3与Bcl-2在胃癌组织中的表达无显著性差异(P>0.05);Galectin-3的阳性表达与癌组织的分化程度无关,但在有淋巴结转移的癌组织中表达水平显著提高(P<0.05);胃癌中Galectin-3与Bcl-2的表达在临床高分期时显著增强(P<0.05)。结论Galectin-3及Bcl-2是良好的胃癌组织表面标记物,在进展期胃癌及有淋巴结转移的胃癌中表达增高,可用于胃癌的诊断,且Galectin-3与Bcl-2的表达有明显相关性,可能存在共同的抗凋亡细胞内信号通路。
Objective To investigate the relationship between the expression of Galectin-3 and clinicopathological features in gastric cancer and to explore the correlation between the expression of Galectin-3 and Bcl-2 in gastric cancer. Methods The expressions of Galectin-3 and Bcl-2 in 60 cases of gastric cancer tissues were detected by immunohistochemistry. Meanwhile, 15 cases of paracancerous tissues were randomly selected as the control group for detection. Results The expression rates of Galectin-3 and Bcl-2 in gastric cancer tissues were 76.7% (46/60) and 68.3% (41/60), respectively, much higher than those in paracancerous tissues (3/15) and 40% (6/15). There was no significant difference in the expression of Galectin-3 and Bcl-2 in gastric cancer (P> 0.05). The positive expression of Galectin-3 was not related to the differentiation of cancer tissues, but significantly increased in the tissues with lymph node metastasis (P <0.05). The expression of Galectin-3 and Bcl-2 in gastric cancer was significantly increased in clinical stage (P <0.05). Conclusions Galectin-3 and Bcl-2 are good markers of gastric cancer tissue surface. They are highly expressed in advanced gastric cancer and gastric cancer with lymph node metastasis and can be used for the diagnosis of gastric cancer, and the expressions of Galectin-3 and Bcl-2 are significantly correlated There may be a common anti-apoptotic intracellular signaling pathway.